论文信息 - A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients. - 字舞流文

A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients.

M. Boccadoro | D. B. Yehuda | F. Cavallo | F. Raimondo | V. Montefusco | A. Palumbo | I. Hardan | T. Caravita | F. Rossini | P. Omedè